Eloxx Pharmaceuticals, an Israel-based developer of treatments for genetic diseases, has raised $30m in series C funding after closing a $6m extension from VC firms Korea Investment Partners and DSC Investments.
The round was co-led by medical diagnostics technology provider Opko Health, VC firm Pontifax and Phil Frost, who is chairman of Opko and a board member of biopharmaceutical firm Sevion Therapeutics.
Eloxx Pharmaceuticals is working on therapies for genetic diseases caused by nonsense mutations. Approximately 3% to 4% of…
